array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2753) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(89) "Assetmark Inc. Has $109.31 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Assetmark Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,980 shares of the biopharmaceutical compa" ["url"]=> string(135) "https://www.marketbeat.com/instant-alerts/assetmark-inc-has-10931-million-stake-in-regeneron-pharmaceuticals-inc-nasdaqregn-2024-11-09/" ["image_url"]=> NULL ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-09" ["categories"]=> array(4) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(11) "Regulations" [2]=> string(12) "Stock Market" [3]=> string(18) "General Investment" } } [1]=> array(7) { ["title_en"]=> string(97) "Harvest Portfolios Group Inc. Sells 7,046 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Harvest Portfolios Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's sto" ["url"]=> string(144) "https://www.marketbeat.com/instant-alerts/harvest-portfolios-group-inc-sells-7046-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-2024-11-06/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dccc8212-3a85-4003-bde6-62fcf8c852ab" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-06" ["categories"]=> array(7) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(11) "Acquisition" [2]=> string(18) "General Investment" [3]=> string(12) "Stock Market" [4]=> string(24) "Stock Research & Ratings" [5]=> string(11) "Regulations" [6]=> string(10) "Divestment" } } [2]=> array(7) { ["title_en"]=> string(112) "Empire Life Investments Inc. Makes New $5.03 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Empire Life Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 4,785 shares of the biopharmaceutical company's stock, valued at approximately $5,03" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-11-03/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1250fdd7-ae26-483d-bfbb-211135737c7f" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-03" ["categories"]=> array(5) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(18) "General Investment" [2]=> string(12) "Stock Market" [3]=> string(19) "Investment Requests" [4]=> string(11) "Regulations" } } [3]=> array(7) { ["title_en"]=> string(107) "Smithbridge Asset Management Inc. DE Acquires 2,503 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Smithbridge Asset Management Inc. DE grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 75.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 5,806 shares of the biopharmaceutical company's stock after buying an addi" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-10-28/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f72da817-0446-46be-8138-98f2c8016cf9" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-10-28" ["categories"]=> array(5) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(11) "Acquisition" [2]=> string(12) "Stock Market" [3]=> string(24) "Stock Research & Ratings" [4]=> string(11) "Regulations" } } [4]=> array(7) { ["title_en"]=> string(97) "Boston Common Asset Management LLC Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Boston Common Asset Management LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 10.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,076 shares of the biopharmaceutical company" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-10-11/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d3d2f360-6915-4ee9-b71c-f174493c50ad" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-10-11" ["categories"]=> array(2) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(11) "Regulations" } } [5]=> array(7) { ["title_en"]=> string(93) "Bard Financial Services Inc. Sells 25 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(221) "Bard Financial Services Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC." ["url"]=> string(132) "https://www.defenseworld.net/2024/10/06/bard-financial-services-inc-sells-25-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/21f5e073-731a-4985-ab8d-1b580f9db0bb" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-10-06" ["categories"]=> array(7) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(18) "General Investment" [2]=> string(12) "Stock Market" [3]=> string(24) "Stock Research & Ratings" [4]=> string(11) "Regulations" [5]=> string(24) "Quarterly/Annual Figures" [6]=> string(10) "Divestment" } } [6]=> array(7) { ["title_en"]=> string(100) "Anchor Investment Management LLC Sells 1,185 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Anchor Investment Management LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 81.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 275 shares of the biopharmaceutical company'" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-10-05/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/18d0ef4b-994d-4eae-adad-343da090c6af" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-10-05" ["categories"]=> array(6) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(18) "General Investment" [2]=> string(12) "Stock Market" [3]=> string(24) "Stock Research & Ratings" [4]=> string(11) "Regulations" [5]=> string(10) "Divestment" } } [7]=> array(7) { ["title_en"]=> string(87) "Norden Group LLC Acquires 6,740 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(231) "Norden Group LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2,572.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC)." ["url"]=> string(126) "https://www.defenseworld.net/2024/07/05/norden-group-llc-acquires-6740-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bac8cc74-b2e8-40db-ad01-f02dae9edaf4" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-07-05" ["categories"]=> array(5) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(11) "Acquisition" [2]=> string(12) "Stock Market" [3]=> string(24) "Stock Research & Ratings" [4]=> string(11) "Regulations" } } [8]=> array(7) { ["title_en"]=> string(98) "Stifel Financial Corp Has $36.61 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(299) "Stifel Financial Corp boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 34.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,679 shares of the biopharmaceutical company's stock" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-06-01/" ["image_url"]=> NULL ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-06-01" ["categories"]=> array(5) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(18) "General Investment" [2]=> string(12) "Stock Market" [3]=> string(11) "Regulations" [4]=> string(24) "Quarterly/Annual Figures" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(266) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(117) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(63) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(61) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(44) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(21) } } } c469a-us-regeneron-pharmaceuticals-inc